Repligen Corporation

RGENNASDAQHealthcare● Active

$122.31

$-4.24(-3.35%)

Market Cap$6.9B

P/E Ratio—

52W High$175.77

52W Low$100.99

Avg Volume1.1M

Open$125.95

Beta1.08

Free Cash Flow Financials Revenue

Repligen Corporation (RGEN) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

RGEN · free cash flow · updated Jun 8, 2026

Core FCF metrics

RGEN · FCF · TTM · margin & CAGR

Free cash flow was $93.9M for FY2025 (fiscal year ending 2025-12-31), down 34.1% year-over-year The FCF margin was 12.7%. Five-year CAGR stands at +20.9%.

FY2025 Free Cash Flow$93.9M▼ -34.1% YoY

Trailing 12M (TTM)$104.1Mtrailing 4 quarters sum

FCF Margin12.7%$93.9M ÷ revenue

3-Year CAGR+34.3%FY2022 → FY2025

5-Year CAGR+20.9%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

RGEN · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$117.4M(24M)$93.9M▼ 34.1%12.7%

FY2024$175.4M(33M)$142.5M▲ +90.2%22.5%

FY2023$113.9M(39M)$74.9M▲ +93.4%11.8%

FY2022$172.1M(133M)$38.7M▼ 18.9%4.8%

FY2021$119.0M(71M)$47.7M▲ +31.6%7.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

RGEN · P/FCF · FCF yield · FCF per share

Repligen Corporation (RGEN) trades at a FCF yield of 1.51% and a price-to-free-cash-flow ratio of 66.1x. FCF per share stands at $1.85, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

1.51%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.85

TTM FCF ÷ Shares Outstanding

Price / FCF

x66.1

Share Price ÷ FCF per Share

EV / FCF (TTM)

x67.3

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

RGEN · cash flow statement · operating / investing / financing

For FY2025, Repligen Corporation generated $117.4M in operating cash flow and spent 24M in capital expenditures, yielding $93.9M in free cash flow.

Operating Activities

+$117.4M

Cash from core business operations

2025-12-31

Investing Activities

−$298.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$15.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($117.4M) − |CapEx| (24M) = FCF ($93.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

RGEN vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Repligen CorporationYOU

RGEN

$93.9M-34.1%12.7%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Repligen Corporation (RGEN) reported free cash flow of $93.9M for FY2025 (fiscal year ending 2025-12-31), down 34.1% year-over-year. The FCF margin was 12.7%.

Based on available data, Repligen Corporation has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $142.5M in FY2024. The 5-year CAGR stands at +20.9%.

Repligen Corporation's FCF yield is 1.51% and price-to-FCF ratio is 66.1x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

RGEN free cash flow · 8 questions

Repligen Corporation free cash flow was $93.9M for FY2025, down 34.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $104.1M.

RGEN free cash flowRGEN FCFRGEN FCF 2025RGEN free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Repligen Corporation · Repligen Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026